If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Abrupt discontinuation
Safety concerns associated with temporary interruption or abrupt discontinuation of teriparatide therapy have not been identified.
has not identified any safety concerns, including adverse reactions
or side effects, associated with temporary interruption or withdrawal
of teriparatide therapy during our clinical studies or follow-up
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid
hormone (1-34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N Engl J Med.
Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide
[human parathyroid hormone (1-34)] therapy on bone density in men
with osteoporosis. J Bone Miner Res. 2003;18(1):9-17.
Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture
risk reduction after withdrawal of teriparatide in postmenopausal
women with osteoporosis. Arch Intern Med. 2004;164(18):2024-2030.
Silverman S, Miller P, Sebba A, et al. The direct assessment of
nonvertebral fractures in community experience (DANCE) study: 2-year
nonvertebral fragility fracture results. Osteoporos Int.
Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide
versus alendronate for treating glucocorticoid-induced osteoporosis:
thirty-six-month results of a randomized, double-blind, controlled
trial. Arthritis Rheum. 2009;60(11):3346-3355.
Forsteo [package leaflet]. Eli Lilly Nederland B.V., The
= Eli Lilly and Company
Date of Last Review:November 11, 2019
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org